Spyre TherapeuticsSYRE
About: Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Employees: 60
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 24
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
25% more capital invested
Capital invested by funds: $1.21B [Q2] → $1.51B (+$304M) [Q3]
10% more funds holding
Funds holding: 107 [Q2] → 118 (+11) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
0.26% less ownership
Funds ownership: 101.16% [Q2] → 100.9% (-0.26%) [Q3]
53% less call options, than puts
Call options by funds: $18K | Put options by funds: $38K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Baird Colleen Kusy 33% 1-year accuracy 7 / 21 met price target | 178%upside $65 | Outperform Maintained | 13 Nov 2024 |
Guggenheim Yatin Suneja 29% 1-year accuracy 6 / 21 met price target | 178%upside $65 | Buy Maintained | 25 Oct 2024 |
Financial journalist opinion
Based on 23 articles about SYRE published over the past 30 days